Abstract
Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy. However, newer advances in the understanding of the molecular pathogenesis of different subtypes of thyroid cancer have provided new opportunities for the evaluation of molecularly targeted therapies. This has led to multiple clinical trials using various multi-kinase inhibitors and the subsequent US FDA approval of sorafenib for differentiated thyroid cancer and vandetanib and cabozantinib for medullary thyroid carcinoma. This review provides a summary of the current literature for the treatment of advanced thyroid carcinoma and future directions in this disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 311-324 |
| Number of pages | 14 |
| Journal | Targeted Oncology |
| Volume | 10 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 5 2015 |
Keywords
- Molecularly targeted therapies
- Multi-kinase inhibitors
- Thyroid cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Pharmacology (medical)